Showing 141-150 of 1310 results for "".
- ICYMI: Vaseline, CVS Partner to Bridge the Gap of Skin Care Inequities in People of Colorhttps://practicaldermatology.com/news/icymi-vaseline-cvs-partner-to-bridge-the-gap-of-skin-care-inequities-in-people-of-color/2461988/Vaseline’s recent Train the Trainer webinar helped educate CVS field leaders on the skin care inequities that exist for Black and Brown populations as part of the brand’s ongoing partnership with CVS Health. During the webcast, Boston area-based dermatologi
- Dan Walker Named VP of US Commercial Operations at SciBasehttps://practicaldermatology.com/news/dan-walker-named-vp-of-us-commercial-operations-at-scibase/2461977/Dan Walker is SciBase’s new VP of US Commercial Operations. SciBase's products include Nevisense and Nevisense Go which address melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. Mr. Walker was previously Senior Dire
- New CEO for SciBasehttps://practicaldermatology.com/news/new-ceo-for-scibase/2461967/Pia Renaudin is SciBase’s new Chief Executive Officer (CEO), effective October 1st, 2023. SciBase's products include Nevisense and Nevisense Go and address melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Ms.
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- Venus Concept Announces Medical Advisory Board for AI.ME, Its Next Generation Robotic Platformhttps://practicaldermatology.com/news/venus-concept-announces-medical-advisory-board-for-aime-its-next-generation-robotic-platform/2461872/Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technolo
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimi
- Spotlight on the Skin of Color Societyhttps://practicaldermatology.com/news/spotlight-on-the-skin-of-color-society/2461823/It’s almost the Skin of Color Society’s (SOCS) 20th anniversary, and the group will be celebrating with several signature programs and new initiatives aimed at bringing greater diversity to dermatology, reducing healthcare disparities, advancing research, expanding training and m
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit